Author

Matthew Kase

Observed names: Kase, Matthew, M. Kase

Observed institutions: Johns Hopkins University, Horizon Discovery (United Kingdom), Menarini Group (Italy), Tempus Labs (United States), Century Therapeutics (United States), The Jackson Laboratory for Genomic Medicine, Menarini Silicon Biosystems (Italy)

OpenAlex ID: A5077380325

Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer

2022 · Minetta C. Liu, Matthew MacKay, et al. · JCO Precision Oncology · 25

Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations

2023 · Minoru Miyashita, Joshua S. K. Bell, et al. · Breast Cancer Research · 24

Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data

2020 · Louis E. Fernandes, Caroline G. Epstein, et al. · Clinical Breast Cancer · 23

Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer

2022 · Yinjie Gao, Michelle M. Stein, et al. · Cancer Immunology Immunotherapy · 13

392 Stage and survival in breast cancer in Estonia: the EUROCARE high-resolution study

2003 · A. Kupp, M. Kase, et al. · European Journal of Cancer Supplements

Works count: 12

Citation count: 85

H-index: 4

I10-index: 4